{"id":"NCT00251979","sponsor":"AstraZeneca","briefTitle":"A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer","officialTitle":"A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2005-11-11","resultsPosted":"2011-06-17","lastUpdate":"2011-06-17"},"enrollment":1312,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Gastrointestinal Hemorrhage"],"interventions":[{"type":"DRUG","name":"Esomeprazole","otherNames":[]}],"arms":[],"summary":"This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.","primaryOutcome":{"measure":"Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo","timeFrame":"Within 72 hours","effectByArm":[{"arm":"Esomeprazole","deltaMin":22,"sd":null},{"arm":"Placebo","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":78,"countries":["Austria","Denmark","Finland","France","Germany","Greece","Hong Kong","Netherlands","Norway","Romania","Russia","South Africa","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["28070941","21181319","20151726","19221370"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":61},"commonTop":["PYREXIA","CONSTIPATION","NAUSEA","HEADACHE","ABDOMINAL PAIN UPPER"]}}